Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | HTR6 | P50406 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4295393 | 1.00 | CA2 (0.50) | CA2HTR6ALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL1136635 | 1.00 | CA2 (0.50) | CA2HTR6ALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL12864006 | 0.89 | CA2 (0.52) | CA2HTR6HTR2CHTR2B | |
| SCHEMBL1136648 | 0.86 | HTR6 (0.48) | CA2HTR6HTR2CHTR2B | |
| SCHEMBL1018563 | 0.86 | CA2 (0.48) | CA2ALDH1A1CYP3A4CYP2D6TSHR | |
| SCHEMBL4970970 | 0.85 | CA2 (0.68) | CA2ALDH1A1CYP3A4CYP2D6TSHR | |
| SCHEMBL7346088 | 0.85 | CA2 (0.68) | CA2ALDH1A1CYP3A4CYP2D6TSHR | |
| SCHEMBL6348557 | 0.85 | CA2 (0.68) | CA2ALDH1A1CYP3A4CYP2D6TSHR | |
| SCHEMBL1043201 | 0.83 | CA2 (0.47) | CA2ALDH1A1CYP3A4CYP2D6TSHR | |
| SCHEMBL13230301 | 0.80 | CA2 (0.51) | CA2ALDH1A1CYP3A4CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2027104-B1 | ARYLSULFONYLCHROMANS AS 5-HT6 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-02-23 | — | — | EP | disclosed |
| EP-2027104-B1 | ARYLSULFONYLCHROMANS AS 5-HT6 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-02-23 | — | — | EP | disclosed |
| US-7754759-B2 | Arylsulfonyl chromans as 5-HT6 inhibitors | ROCHE PALO ALTO LLC (US) | 2010-07-13 | — | — | US | disclosed |
| US-7754759-B2 | Arylsulfonyl chromans as 5-HT6 inhibitors | ROCHE PALO ALTO LLC (US) | 2010-07-13 | — | — | US | disclosed |
| WO-2007051735-A1 | ARYLSULFONYLCHROMANS AS 5-HT6 INHIBITORS INDOLYLMALEIMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-10 | — | — | WO | disclosed |
| US-20070099908-A1 | Arylsulfonyl chromans as 5-HT6 inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099908-A1 | Arylsulfonyl chromans as 5-HT6 inhibitors | HTR6, HTR1F, HTR1A | CA2 4390/4885HTR6 1/4885ALDH1A1 1927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.